By Michael Dabaie

Celgene Corp. (CELG) said the U.S. Food and Drug Administration approved Otezla 30 mg twice daily for adults with oral ulcers associated with Behcet's Disease.

Behcet's Disease is a rare, chronic, multisystem inflammatory disease that is difficult to treat, Celgene said. Otezla reduced the number and pain of oral ulcers in a 12-week placebo-controlled Phase 3 study.

Otezla is now approved for three indications in the U.S., including the treatment of patients with moderate to severe plaque psoriasis, the company said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

July 19, 2019 14:32 ET (18:32 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Celgene Charts.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Celgene Charts.